<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511432</url>
  </required_header>
  <id_info>
    <org_study_id>VX11-950-025</org_study_id>
    <nct_id>NCT01511432</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects</brief_title>
  <official_title>A Two-Part, Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of 3 Novel Oral Formulations of Telaprevir Relative to Incivek 375-mg Tablets When Administered as a Single 1125-mg Dose to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the relative bioavailability, safety, and
      tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters: Maximum plasma concentration (Cmax), area under the concentration versus time curve (AUC) from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>Up to 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• PK parameters: Maximum plasma concentration (Cmax), area under the concentration versus time curve AUC from time 0 to last time point (AUC0-tlast)</measure>
    <time_frame>Up to 57 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of 3 oral formulations of telaprevir as assessed by adverse events, serious adverse events and results of clinical laboratory tests (serum chemistry, hematology, and urinalysis), vital signs, and 12-lead electrocardiograms</measure>
    <time_frame>Up to 57days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax after dosing (tmax) and terminal half-life (t1/2) of telaprevir</measure>
    <time_frame>Up to 57 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A will be a 4-formulation, 4-sequence, 4-period crossover relative bioavailability study of 3 novel oral telaprevir formulations relative to the 375-mg Incivek tablet in the fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B will be a 2-formulation, 6-sequence, 3-period cross-over relative bioavailability study of the novel oral telaprevir formulation selected from Part A in the fasted relative to the fed state and relative to the 375-mg Incivek tablet in the fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telaprevir formulation A</intervention_name>
    <description>A single 1125-mg dose administered orally</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telaprevir Formulation B</intervention_name>
    <description>A single 1125-mg dose administered orally</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telaprevir Formulation C</intervention_name>
    <description>A single 1125-mg dose administered orally</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telaprevir Formulation D</intervention_name>
    <description>A single 1125-mg dose administered orally</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects (male and female of non-childbearing potential) between the ages of
             18 and 55 years

          -  Non-childbearing potential female subjects

          -  Male subjects and female partners must agree to use at least 2 methods of
             contraception

          -  Subjects with a body mass index (BMI) of 18 to 30 kg/m2 and weigh &gt;50 kg at the
             Screening Visit.

        Exclusion Criteria:

          -  Subjects with a positive test result for hepatitis B, hepatitis C, or HIV

          -  Subjects with a significant history of any illness, as deemed important by the
             investigator or any condition possibly affecting drug absorption

          -  Subjects with a positive urine screen for drugs of abuse

          -  Subjects with a history of regular alcohol consumption

          -  Subjects treated with an investigational drug within 30 days

          -  For Part A only: Subjects with 12-lead ECG QTcF &gt;450 msec (males) or QTcF &gt;470 msec
             (females) at the Screening Visit

          -  Subjects who use prescription and/or nonprescription medications or vitamins and/or
             dietary supplements

          -  Subjects who have made a blood donation of approximately 1 pint (500 mL) within 56
             days prior to the first dose of study drug

          -  Subjects who have a female partner who is pregnant, nursing, or planning to become
             pregnant during the study or within 90 days of the last dose of study drug

          -  Subjects on hormone replacement therapy (HRT) must discontinue such therapy 28 days
             prior to the first dose of study drug

          -  Subjects who have a habit of using tobacco or nicotine containing products within 6
             months before the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relative bioavailability</keyword>
  <keyword>telaprevir formulations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

